Literature DB >> 20805397

In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.

F Javier Pastor1, Mery Ruíz-Cendoya, Isabel Pujol, Emilio Mayayo, Deanna A Sutton, Josep Guarro.   

Abstract

We have determined the in vitro activities of amphotericin B (AMB), voriconazole, posaconazole (PSC), itraconazole (ITC), ravuconazole, terbinafine, and caspofungin against five strains of Cunninghamella bertholletiae and four of Cunninghamella echinulata. The best activity was shown by terbinafine against both species (MIC range = 0.3 to 0.6 μg/ml) and PSC against Cunninghamella bertholletiae (MIC = 0.5 μg/ml). We have also evaluated the efficacies of PSC, ITC, and AMB in neutropenic and diabetic murine models of disseminated infection by Cunninghamella bertholletiae. PSC at 40, 60, or 80 mg/kg of body weight/day was as effective as AMB at 0.8 mg/kg/day in prolonging survival and reducing the fungal tissue burden in neutropenic mice. PSC at 80 mg/kg/day was more effective than AMB at 0.8 mg/kg/day in reducing the fungal load in brain and lung of diabetic mice. Histological studies revealed an absence of fungal elements in organs of mice treated with either AMB at 0.8 mg/kg/day or PSC at 60 or 80 mg/kg/day in both models. ITC showed limited efficacy in both models. PSC could be a therapeutic option for the treatment of systemic infections caused by Cunninghamella bertholletiae.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805397      PMCID: PMC2976138          DOI: 10.1128/AAC.00786-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 2.  Zygomycosis: the re-emerging fungal infection.

Authors:  M Chayakulkeeree; M A Ghannoum; J R Perfect
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

3.  Report of a successful treatment of pulmonary Cunninghamella bertholletiae infection with liposomal amphotericin and posaconazole in a child with GvHD and review of the literature.

Authors:  Jorge Garbino; Catherine Myers; Juan Ambrosioni; Fabienne Gumy-Pause
Journal:  J Pediatr Hematol Oncol       Date:  2010-03       Impact factor: 1.289

4.  Nosocomial invasive infection caused by Cunninghamella bertholletiae: case report.

Authors:  Xisto Sena Passos; Werther Souza Sales; Patrícia Jackeline Maciel; Carolina Rodrigues Costa; Denise Milioli Ferreira; Maria Rosário Rodrigues do Silva
Journal:  Mycopathologia       Date:  2006-01       Impact factor: 2.574

Review 5.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

6.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  Spectrum of zygomycete species identified in clinically significant specimens in the United States.

Authors:  E Alvarez; D A Sutton; J Cano; A W Fothergill; A Stchigel; M G Rinaldi; J Guarro
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

Review 8.  Treatment of zygomycosis: current and new options.

Authors:  Thomas R Rogers
Journal:  J Antimicrob Chemother       Date:  2008-01       Impact factor: 5.790

9.  Streptozocin-induced diabetic mouse model of urinary tract infection.

Authors:  David A Rosen; Chia-Suei Hung; Kimberly A Kline; Scott J Hultgren
Journal:  Infect Immun       Date:  2008-07-21       Impact factor: 3.441

View more
  3 in total

Review 1.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

2.  In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.

Authors:  Valentina Salas; F Javier Pastor; Enrique Calvo; Eduardo Alvarez; Deanna A Sutton; Emilio Mayayo; Anette W Fothergill; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 3.  Biology, systematics, and clinical manifestations of Zygomycota infections.

Authors:  A Muszewska; J Pawłowska; P Krzyściak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-11       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.